一种对衰老敏感的补偿分泌脂酶,能提供神经保护和认知性
Cinzia Vicidomini1,2,3,4, Travis D Goode1,2,3,4, Kathleen M McAvoy1,2,3,4
1Center for Regenerative Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA.
bioRxiv : the preprint server for biology
|August 30, 2024
概括
研究人员发现,在老化的大脑细胞中增强PLA2G2F酶可以防止突触损失和记忆力下降,这可能为阿尔茨海默病 (AD) 提供一种新的策略. 这一发现强调了PLA2G2F作为在衰老期间保持大脑健康的关键因素.
科学领域:
- 神经科学是一个神经科学.
- 分子生物学分子生物学
- 衰老研究研究 衰老研究
背景情况:
- 脂质稳态分解与衰老和神经退行性疾病 (如阿尔茨海默氏症) 有关.
- 老化大脑中的补偿机制对于认知储备至关重要,但仍然不太了解.
- 识别这些保护因素对于理解和减轻与年龄相关的认知衰退至关重要.
研究的目的:
- 在老化的大脑中识别新的补偿机制,以保持认知功能.
- 为了研究分泌的脂酶Pla2g2f在与衰老相关的神经保护中的作用.
- 探索PLA2G2F作为阿尔茨海默病和认知衰退的治疗点.
主要方法:
- 在衰老过程中查参与牙状颗粒细胞 (DGC) 突触损失的因素.
- 在老化小鼠的DGC中Pla2g2f表达的基因操纵和AD模型.
- 评估病理生理变化,包括突触完整性,神经炎症,神经发生和脂质代谢.
- 评估海马体依赖记忆功能和粉样蛋白病理.
主要成果:
- 在衰老过程中,Pla2g2f表达增加了DGCs,并防止突触损失.
- 删除Pla2g2f会加剧与衰老相关的缺陷,包括记忆障碍和神经炎症.
- 增强 Pla2g2f 保护突触,减少神经炎症,并改善老化和AD模型中的记忆.
- 神经元的PLA2G2F信号减少了微质中的脂质滴积累,维持了脂质平衡.
结论:
- 在老化的大脑中,PLA2G2F充当补偿性神经保护因子.
- 通过PLA2G2F维持脂质稳定对于抵消与年龄相关的认知衰退至关重要.
- 准PLA2G2F为阿尔茨海默病和认知衰老提供了一个有前途的治疗策略.
更多相关视频
09:44Chemogenetic Regulation in Reprogrammed Stem Cell-derived Precursor Cells in Treating Neurodegenerative Diseases
Published on: May 2, 2025
114
07:08A High Throughput, Multiplexed and Targeted Proteomic CSF Assay to Quantify Neurodegenerative Biomarkers and Apolipoprotein E Isoforms Status
Published on: October 20, 2016
7.8K
相关概念视频
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
110
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
110
01:01Neuroplasticity
314
Neuroplasticity reflects the brain's remarkable capacity to adapt and evolve, responding dynamically to learning, experiences, or injury by reorganizing its neural circuitry. This reorganization involves creating new neural connections and refining old ones through a series of biological processes that contribute to the brain's lifelong development and adaptability.
314
01:26Alzheimer's Disease: Overview
454
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
454
01:30Cognitive Development During Adulthood
72
Cognitive development continues throughout adulthood, undergoing significant shifts across early, middle, and late stages. Individual transition occurs from adolescent idealism to pragmatic and adaptable thinking in early adulthood. During this period, individuals learn to integrate personal beliefs with the recognition that other perspectives are equally valid. Exposure to the complexities of modern society, diverse experiences, and higher education contribute to this adaptive thought process,...
72
01:03Long-term Depression
2.5K
Long-term depression, or LTD, is one of the ways by which synaptic plasticity—changes in the strength of chemical synapses—can occur in the brain. LTD is the process of synaptic weakening that occurs over time between pre and postsynaptic neuronal connections. The synaptic weakening of LTD works in opposition to synaptic strengthening by long-term potentiation (LTP) and together are the main mechanisms that underlie learning and memory.
Calcium Ion Concentration Mechanism
If over...
Calcium Ion Concentration Mechanism
If over...
2.5K
01:22Alzheimer's Disease: Treatment
170
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
170